Adam Grossman
Chief Executive Officer at ADMA BIOLOGICS, INC.
Net worth: 28 M $ as of 2024-04-29
Network origin in Adam Grossman first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
| Public Company | Biotechnology | 30 | |
BioFlorida, Inc.
 BioFlorida, Inc. Miscellaneous Commercial ServicesCommercial Services BioFlorida, Inc. is an organization that represents the life science industry in Florida. The private company is based in Florida and represents over 6,700 establishments and research organizations in the biopharmaceutical, medical technology, and bioagriculture sectors, providing employment to 94,000 Floridians. The American company's initiatives aim to create a favorable business environment for the development of innovative products and technologies that enhance people's lives and bring economic benefits to the state. Nancy K. Bryan has been the CEO of the company since 2013.
24
| Private Company | Miscellaneous Commercial Services | 24 |
ADMA Plasma Biologics, Inc.
 ADMA Plasma Biologics, Inc. BiotechnologyHealth Technology ADMA Plasma Biologics, Inc. develops medicines for the treatment of infectious diseases. The company was founded in 2007 and is headquartered in Hackensack, NJ.
4
| Subsidiary | Biotechnology | 4 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Adam Grossman via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
Alliance for Regenerative Medicine
 Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Medical/Nursing Services | Director/Board Member Director/Board Member Director/Board Member | |
| University of Maryland | College/University | Undergraduate Degree Undergraduate Degree Doctorate Degree | |
| Florida State University | College/University | Undergraduate Degree Undergraduate Degree Graduate Degree | |
| NEUBASE THERAPEUTICS, INC. | Pharmaceuticals: Major | Chairman Director/Board Member | |
| Rutgers State University of New Jersey | College/University | Undergraduate Degree Masters Business Admin | |
| APPLIED GENETIC TECHNOLOGIES CORPORATION | Pharmaceuticals: Generic | Director of Finance/CFO Chief Executive Officer | |
Xhale, Inc.
 Xhale, Inc. Medical SpecialtiesHealth Technology Xhale, Inc. operates as a medical technology company. It develops and commercializes patient-centric monitoring solutions for the healthcare industry. The firm specializes in biotechnology, medical devices, clinical trials monitoring, and breath diagnostics. The company was founded by Richard J. Melker and Donn M. Dennis in 2005 and is headquartered in Gainesville, FL. | Medical Specialties | Director/Board Member Corporate Officer/Principal | |
| Warrington College of Business Administration | College/University | Masters Business Admin Graduate Degree | |
Baxter Healthcare Corp.
 Baxter Healthcare Corp. Medical SpecialtiesHealth Technology Baxter Healthcare Corp. develops, manufactures, and distributes hospital supplies and medical technologies. It distributes medical treatment options for conditions such as hemophilia, immune disorders, kidney disease, cancer, and trauma. The company was founded on June 21, 1967 and is headquartered in Deerfield, IL. | Medical Specialties | Corporate Officer/Principal Sales & Marketing | |
| AIM IMMUNOTECH INC. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
| University of Florida | College/University | Masters Business Admin Doctorate Degree | |
| GAIN THERAPEUTICS, INC. | Biotechnology | Director/Board Member Director/Board Member | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Corporate Officer/Principal Corporate Officer/Principal | |
| Michigan State University | College/University | Undergraduate Degree Undergraduate Degree | |
ZyVersa Therapeutics Operating, Inc.
 ZyVersa Therapeutics Operating, Inc. Pharmaceuticals: MajorHealth Technology ZyVersa Therapeutics Operating, Inc. operates as a specialty pharmaceutical company, which develops and commercializes prescription pharmaceutical products. The firm focuses on developing products for the treatment of men?s health, as well as for other markets where current therapies are suboptimal and underdeveloped. It offers VAR 100, an oral formulation of native testosterone to treat male hypogonadism; and VAR 200 that minimizes and prevents kidney cell damage, and improves focal segmental glomerulosclerosis prognosis. The company was founded by Stephen C. Glover and Shawn M. Titcomb in 2014 and is headquartered in Weston, FL. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| THERAPEUTICSMD, INC. | Pharmaceuticals: Major | Founder Chief Executive Officer | |
| State University of New York at Albany | College/University | Undergraduate Degree Undergraduate Degree | |
| Stanford University | College/University | Undergraduate Degree Undergraduate Degree | |
| ESPERION THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
| University of California, Berkeley | College/University | Undergraduate Degree Undergraduate Degree | |
Aisling Capital LLC
 Aisling Capital LLC Investment ManagersFinance Aisling Capital LLC (Aisling Capital) is an venture capital firm founded in 1999 by Dennis Joseph Purcell. The firm is headquartered in New York, New York. | Investment Managers | Private Equity Investor Private Equity Investor | |
| LOXO ONCOLOGY INC | Pharmaceuticals: Major | Director of Finance/CFO Director/Board Member | |
| NEUROBO PHARMACEUTICALS, INC. | Biotechnology | Director/Board Member | |
Otsuka America Pharmaceutical, Inc.
 Otsuka America Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Otsuka America Pharmaceutical, Inc. manufactures and supplies pharmaceutical products. It develops drugs for neuroscience, cardiovascular, and gastrointestinal treatments. The company was founded in 1989 and is headquartered in Rockville, MD. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| OLD API WIND-DOWN LTD. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| State University of New York College at Oswego | College/University | Undergraduate Degree | |
| PULSE EVOLUTION CORPORATION | Information Technology Services | Investor Relations Contact | |
| ZEVRA THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Vycellix, Inc.
 Vycellix, Inc. BiotechnologyHealth Technology Vycellix, Inc. is a life science company that specializes in the development of cell and gene-based therapies for various medical conditions such as hematology/oncology, autoimmunity/chronic inflammatory diseases, and organ/tissue transplantation. The private company is based in Tampa, FL. The company's platforms were discovered by scientists at the Karolinska Institutet in Sweden, which is known for its Nobel Assembly. Vycellix is headquartered in the United States, with scientific operations in Sweden. The company's mission is to develop and commercialize optimized, next-generation T cell and natural killer (NK) cell-based cancer therapies using its transformational Vy-UC universal cell technology. The CEO of the company is Evren Alici. | Biotechnology | President | |
| POZEN INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
VyGen-Bio, Inc.
 VyGen-Bio, Inc. BiotechnologyHealth Technology Part of Coeptis Therapeutics Holdings, Inc., VyGen-Bio, Inc. develops cell and gene therapies and treatments for cancer. The private company is based in Tampa, FL. The CEO of the company is Evren Alici. VyGen-Bio was acquired by Coeptis Therapeutics Holdings, Inc. | Biotechnology | President | |
| AUXILIUM PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Sales & Marketing | |
KOS Pharmaceuticals, Inc.
 KOS Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology KOS Pharmaceuticals, Inc. operates as pharmaceutical company that developed and commercialized proprietary prescription products for the treatment of chronic cardiovascular, metabolic and respiratory diseases. The company is founded by Daniel M. Bell and Michael Jaharis in 1988 and is headquartered in Cranbury, NJ. | Pharmaceuticals: Major | Sales & Marketing | |
| The Leonard N Stern School of Business | College/University | Masters Business Admin | |
Vicuron Pharmaceuticals LLC
 Vicuron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Vicuron Pharmaceuticals LLC develops pharmaceutical products. It engages in discovering, developing, manufacturing, and commercializing vital medicine for seriously ill patients. The company offers anidulafungin drug, which prevents cell wall formation and other infectious fungi. It also offers antibiotic for the treatment of complicated skin and soft-tissue infections. The company was founded by Christopher T. Walsh in 1995 and is headquartered in King of Prussia, PA. | Pharmaceuticals: Major | Director of Finance/CFO | |
| Nextgennk | Director/Board Member | ||
| AFFIMED N.V. | Biotechnology | Director/Board Member | |
| Equels Law Firm | Corporate Officer/Principal | ||
| ACHILLES THERAPEUTICS PLC | Pharmaceuticals: Major | Director/Board Member | |
Affimed GmbH
 Affimed GmbH Miscellaneous Commercial ServicesCommercial Services Part of Affimed NV, Affimed GmbH is a clinical leader in innate immuno-oncology. The private company, based in Heidelberg, Germany, develops proprietary cancer-targeting bispecific antibodies that activate the innate immune system to kill tumor cells. Affimed leads clinical development of innate cell engagers for solid/hematologic tumors as monotherapy, in combination with NK cells or with checkpoint inhibitors. Adolf Hoess has been the CEO of the German company since 2010. | Miscellaneous Commercial Services | Director/Board Member | |
Symphogen A/S
 Symphogen A/S Pharmaceuticals: MajorHealth Technology Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark. | Pharmaceuticals: Major | Chairman | |
| BIOTEST AG | Pharmaceuticals: Other | Chairman |
Statistics
International
| United States | 40 |
| Germany | 7 |
| France | 2 |
| Canada | 2 |
| Sweden | 2 |
Sectoral
| Health Technology | 31 |
| Consumer Services | 12 |
| Health Services | 3 |
| Commercial Services | 3 |
| Finance | 2 |
Operational
| Director/Board Member | 190 |
| Corporate Officer/Principal | 86 |
| President | 49 |
| Undergraduate Degree | 46 |
| Independent Dir/Board Member | 40 |
Most connected contacts
| Insiders | |
|---|---|
| Steven Elms | 37 |
| Arnold Kling | 30 |
| Dov Goldstein | 28 |
| Bryant Fong | 23 |
| Eric Richman | 21 |
| John Spencer | 17 |
| Susan B. Washer | 17 |
| Bernhard R. M. Ehmer | 16 |
| Jerrold Grossman | 15 |
| Joseph Sardano | 15 |
| Mark Glickman | 14 |
| Martha Demski | 13 |
| Geoff Green | 12 |
| Thomas Equels | 12 |
| Douglas W. Calder | 12 |
- Stock Market
- Insiders
- Adam Grossman
- Company connections
